MANILA, Philippines — The Food and Drug Administration (FDA) said it will oversee the voluntary recall of infant formula products by Nestlé Philippines, following a potential quality issue over a raw material from a supplier. In a statement on Monday, FDA Director General Paolo Teston said that the precautionary recall will cover limited batches of NAN OPTIPRO and NANKID OPTIPRO. “FDA is verifying the specific affected batches, ensuring the prompt and complete removal of recalled products from physical and online retail outlets, and conducting distribution and communication checks to confirm that recall measures are effectively implemented across the supply chain,” the FDA said in a statement. The FDA said that it is working closely with Nestlé Philippines to identify the specific affected batches. It added that no reports of illness or adverse events have been associated with the recalled products, so far. The FDA urged the public to strictly follow recall instructions issued by the manufacturer. Consumers were advised to carefully check the batch numbers of the infant formula products they purchased. It added that an advisory will be released soon to provide further information and updates for the general public. “The FDA will continue to carry out post-market surveillance, inspections, and product assessments to ensure that all regulated products in the market meet established safety and quality requirements,” it added.